Massive study tests if insurance records can mimic Gold-Standard drug trials

NCT ID NCT04736420

First seen Jun 27, 2026 · Last updated Jul 10, 2026 · Updated 1 time

Summary

This study looks at healthcare claims from over 78,000 people to see if it can reproduce the results of the EINSTEIN-DVT trial, which compared two blood thinners (rivaroxaban and warfarin) for treating blood clots. The goal is not to test a new drug, but to learn whether real-world data can reliably mimic clinical trials. If it works, this approach could help researchers answer questions faster and cheaper using existing health records.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Rivaroxaban and Warfarin
What this could lead to
If successful, this could show that analyzing healthcare claims data can reliably reproduce clinical trial results, potentially speeding up future research.
What could go wrong
This is an observational study using existing data, not a new treatment trial. Results may not perfectly match the original trial due to data limitations or unmeasured factors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for VENOUS THROMBOEMBOLISM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Brigham and Women's Hospital

    Boston, Massachusetts, 02120, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.